Edwards Lifesciences Corporation (EW) Analyst/Investor Day Transcript

Edwards Lifesciences Corporation (EW) Analyst/Investor Day Transcript

Seeking Alpha • Dec 11, 2025

Should You Continue to Hold EW Stock in Your Portfolio?

Edwards Lifesciences leans on growth in Surgical Structural Heart, TAVR and TMTT, though macro pressures and litigation continue to weigh on margins.

Zacks Investment Research • Dec 11, 2025

Edwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) will outline its patient-focused strategy and share financial guidance during its annual investor conference. Entering 2026 with momentum for sustainable differentiated growth, Edwards is uniquely positioned with leading therapies across its core structural heart innovations for patients with aortic stenosis (AS), mitral regurgitation (MR), tricuspid regurgitation (TR) and pulmonic diseases, and expanding into emerging opportuniti.

Business Wire • Dec 4, 2025

HALPER SADEH LLC ENCOURAGES EDWARDS LIFESCIENCES CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Nov. 30, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Edwards Lifesciences Corporation (NYSE: EW) breached their fiduciary duties to shareholders.

PRNewsWire • Nov 30, 2025

Top small-cap plays for 2026

The Investment Committee debates their top small- and mid-cap names for 2026.

CNBC Television • Nov 25, 2025

BSX vs. EW: Which Heart Device Stock Is the Smarter Investment Now?

Boston Scientific's EP breadth, WATCHMAN momentum and acquisitions give it an edge over Edwards in cardiovascular devices.

Zacks Investment Research • Nov 24, 2025

Artisan Global Discovery Fund: Q3 Delivers Strong Results Amid Trimming And Exits

The portfolio generated a modestly positive absolute return in Q3, but it trailed the MSCI All Country World Small Mid Index. The Q3 underperformance was driven by stock selection in the IT, financials and consumer discretionary sectors. On the positive side, stock selection in the health care and industrials sectors was the strongest contributor to performance.

Seeking Alpha • Nov 20, 2025

Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease

NEW ORLEANS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced its founding sponsorship of the American Heart Association's Heart Valve Initiative, a national effort to improve care and outcomes for the more than 28 million people living with heart valve disease worldwide. In the U.S. alone, valve disease contributes to more than 60,000 deaths annually, many driven by delayed diagnosis or treatment. Through this initiative, the American Heart Association is establishing valve dis.

Business Wire • Nov 9, 2025

Is the Options Market Predicting a Spike in Edwards Lifesciences Stock?

Investors need to pay close attention to EW stock based on the movements in the options market lately.

Zacks Investment Research • Nov 5, 2025

EW Stock Gains on Q3 Earnings and Revenue Beat, Margins Crash

Edwards Lifesciences Q3 earnings and sales beat estimates on robust TAVR and TMTT growth, though margins take a sharp hit.

Zacks Investment Research • Oct 31, 2025